SCHEMBL2160707

SCHEMBL2160707

ON=Cc1ccccc1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.59
GRIN3B O60391 2/20 0.59
GRIN1 Q05586 2/20 0.59
GRIN2A Q12879 2/20 0.59
GRIN2B Q13224 2/20 0.59
GRIN2C Q14957 2/20 0.59
GRIN3A Q8TCU5 2/20 0.59
HTT P42858 4/20 0.50
TSHR P16473 2/20 0.50
HPGD P15428 6/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
GFER P55789 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FGF23 Q9GZV9 2/20 0.43
HSD17B10 Q99714 2/20 0.43
BCL2L1 Q07817 1/20 0.43
KCNN4 O15554 2/20 0.42
LMNA P02545 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2160705 1.00 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3323469 1.00 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4887808 0.86 ESR2 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4887803 0.86 ESR2 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7068298 0.84 FGF23 (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14675605 0.79 ALOX5 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL14675604 0.79 ALOX5 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12673190 0.78 GRIN2D (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6779682 0.78 FGF23 (0.57) HTTTSHRHPGDALDH1A1MEN1
SCHEMBL27958563 0.77 GSK3A (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372873-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-12 US disclosed
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-28 US disclosed
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents ASTRAZENECA AB (SE) 2010-06-03 US disclosed
US-7396847-B2 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2008-07-08 US disclosed
US-20060116401-A1 Antibacterial compounds ASTRAZENECA AB (SE) 2006-06-01 US disclosed
US-20060116400-A1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents ASTRAZENECA AB (SE) 2006-06-01 US disclosed
US-20060058314-A1 Oxazolidinone derivatives and their use as antibacterial agents ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1572688-A1 OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Astrazeneca AB (SE) 2005-09-14 EP disclosed
EP-1567521-A1 ANTIBACTERIAL COMPOUNDS AstraZeneca AB (SE) 2005-08-31 EP disclosed
EP-1567532-A1 OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS Astrazeneca AB (SE) 2005-08-31 EP disclosed
EP-1427711-B1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2005-07-13 EP disclosed
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents ASTRAZENECA AB (SE) 2005-05-19 US disclosed
WO-2004056817-A1 OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2004-07-08 WO disclosed
EP-1427711-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS AstraZeneca AB (SE) 2004-06-16 EP disclosed
WO-2004048370-A1 ANTIBACTERIAL COMPOUNDS ASTRAZENECA AB (SE) 2004-06-10 WO disclosed
WO-2004048392-A1 OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2004-06-10 WO disclosed
WO-2003022824-A1 OXAZOLIDINONE AND/OR ISOXAZOLINE AS ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2003-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137243-A1 Oxazolidinone And/Or Isoxazoline As Antibacterial Agents CYP8B1, HRH2, CYP2W1 GRIN2D 421/4885GRIN3B 1333/4885GRIN1 796/4885
US-20050107435-A1 Oxazolidinone and/or isoxazoline as antibacterial agents CYP8B1, CYP2W1, HRH2 GRIN2D 558/4885GRIN3B 1241/4885GRIN1 761/4885
US-20060116401-A1 Antibacterial compounds MRPL21, NR0B2, CYP8B1 GRIN2D 1505/4885GRIN3B 1098/4885GRIN1 830/4885
US-20060058314-A1 Oxazolidinone derivatives and their use as antibacterial agents NR0B1, NR0B2, CYP8B1 GRIN2D 518/4885GRIN3B 593/4885GRIN1 305/4885
US-20060116400-A1 Oxazolidinone and/or isoxazoline derivatives as antibacterial agents NR0B2, NR0B1, HRH2 GRIN2D 326/4885GRIN3B 458/4885GRIN1 385/4885
US-20110182856-A1 INHIBITORS OF SERINE PROTEASES PRSS1, SPINT2, PRSS2 GRIN2D 4559/4885GRIN3B 3675/4885GRIN1 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.